Preventing anthracycline-induced cardiotoxicity with ivabradine: A systematic review and meta-analysis
World Journal of Cardiology · 28.05.2026
DOI: 10.4330/wjc.121472 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift World Journal of Cardiology, online erschienen am 28.05.2026. Verfasst von Rohab Sohail und 13 weiteren Autor:innen.
Abstract (Originalsprache)
BACKGROUND Anthracyclines by generating reactive oxygen species (ROS), causes a dose-dependent, irreversible myocardial injury, resulting in cardiomyopathy and congestive heart failure. Ivabradine is speculated to provide cardio protection against anthracyclines by lowering heart rate, reducing oxygen demand, and preserving coronary microcirculation Our meta-analysis aims to provide a comprehensive conclusion to this association. AIM To investigate the efficacy of Ivabradine in prevention of anthracycline-induced cardiotoxicity. METHODS PubMed and Google Scholar were searched for randomized controlled trials (RCTs) comparing Ivabradine to placebo in patients receiving Anthracycline based chemotherapy. After careful screening 3 studies including 210 patients were analyzed using a random-effects model in RevMan 5.4.1 and results were generated in form of relative risk (RR) and mean difference (MD). RESULTS Ivabradine failed to show any statistical significant reduction in; troponin [SMD = 0.10; 95% confidence interval (95%CI): -2.14 to 2.33; P = 0.93], NT-proBNP (SMD = 0.26; 95%CI: -1.39 to 1.92; P = 0.76), systolic blood pressure (SMD = -0.13; 95%CI: -0.44 to 0.19; P = 0.43), diastolic blood pressure (SMD = -0.16; 95%CI: -047 to 0.16; P = 0.33), global longitudinal strain reduction (RR = 0.80; 95%CI: 0.28-2.32; P = 0.68), or left ventricular ejection fraction (SMD = –0.01; 95%CI: -0.28 to 0.26; P = 0.95). CONCLUSION Our analysis failed to show efficacy of ivabradine in mitigating anthracycline-induced cardiotoxicity. small sample size and heterogeneity limits definitive interpretation, warranting a large-scale RCT with longer follow-up period.
Zitieren
APA
Sohail, R., Khattak, R., Shah, H. H., Khan, Z., Jawed, S., Wasim, A. U., Akram, B., Patel, R., Patel, S., Alam, M., Chaudhry, S., Mehdi, S., Patel, V., & Singh, M. (2026). Preventing anthracycline-induced cardiotoxicity with ivabradine: A systematic review and meta-analysis. World Journal of Cardiology. https://doi.org/10.4330/wjc.121472
Vancouver
Sohail R, Khattak R, Shah HH, Khan Z, Jawed S, Wasim AU, et al. Preventing anthracycline-induced cardiotoxicity with ivabradine: A systematic review and meta-analysis. World Journal of Cardiology. 2026. doi:10.4330/wjc.121472
BibTeX
@article{Sohail2026,
author = {Sohail, Rohab and Khattak, Ridda and Shah, Haider Hussain and Khan, Zaraq and Jawed, Shafaq and Wasim, Asad Ullah and Akram, Bisma and Patel, Rohan and Patel, Simran and Alam, Madihah and Chaudhry, Shahryar and Mehdi, Samar and Patel, Vyom and Singh, Manjeet},
title = {Preventing anthracycline-induced cardiotoxicity with ivabradine: A systematic review and meta-analysis},
journal = {World Journal of Cardiology},
year = {2026},
doi = {10.4330/wjc.121472}
}
EUVIMED